Open Accessibility Menu
  • Certified ALS Center Program
    Certified ALS Center Program
  • Level 4 Epilepsy Center - national association of epilepsy centers
    National Association of Epilepsy Centers
  • Comprehensive Stroke Center
  • AANEM EDX Lab Accreditation - exemplary status
    AANEM EDX Lab Accreditation

Rescue Room

Washington DC Migraine Treatment

Individuals who suffer an acute, severe migraine headache that persists despite self-administered therapy typically have one of two options: either seek care at an emergency room or simply “suffer in silence” until the headache attack eventually ends. The first option is time-consuming, often uncomfortable, costly and not necessarily guaranteed to result in an effective treatment outcome. The discomfort and disadvantages of “suffering in silence” speak for themselves.

Our headache “Rescue Room” offers a third and more attractive alternative. Patients who are actively being followed in The Headache Center and who are experiencing an acute, severe migraine headache that is not responding to self-administered therapy may call the Center Monday-Friday at (202) 677-6823 to request in-clinic treatment.

Treatment Options

Treatment typically involves intravenous hydration and subcutaneous, intramuscular or intravenous administration of a medication or a combination of medications known to be effective in the treatment of a persistent migraine attack. The “Rescue Room” is located within the headache clinic itself, and patients will be treated by providers who are familiar with them and with their headache management.

Note:

  • Acute headache sufferers seeking treatment in the “Rescue Room” should be established patients at The Headache Center who are actively being followed (“actively” implies a clinic visit within the previous 6 months).
  • Patients seeking treatment in the “Rescue Room” ideally should call early in the day to ensure that there is time for them to be evaluated and treated before the clinic’s closing time.
  • Patients may use the “Rescue Room” no more than two times within any 30 day period.
  • Patients presenting to the “Rescue Room” should bring a companion age 18 or older who is capable of transporting them home or to another secure location after treatment has been completed.
  • We do not treat patients with opiates/opioids (‘narcotics’) or other controlled substances in our “Rescue Room.”

Make an appointment with the Rescue Room at (202) 677-6823

Clinical Trials

  • INSYTE: Management of Parkinson’s Disease Psychosis in Actual Practice (The INSYTE Study)

    The INSYTE Study will examine the current disease progression of Parkinson’s disease Psychosis (PDP), the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers.

  • REFALS:EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS

    This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale.

  • PENNANT: A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis

    The purpose of the PENNANT study is to evaluate the safety, tolerability, and effectiveness of the study drug (H.P. Acthar Gel®) in slowing the loss of motor skills or brain function in patients with ALS and to assess whether the study drug can increase an ALS patient’s life expectancy. Eligible participants will either receive the study drug or a placebo (inactive drug).

  • Protocol H8H-MC-LAIJ, Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
    The objective of this Phase 3 study is to evaluate the efficacy of lasmiditan 200 mg and 100 mg on migraine headache pain freedom compared to placebo.
  • ARISE: pAdsevonil in drug-ResIStant Epilepsy: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY, PHASE 2
    The primary objectives of this study are to characterize the dose-response relationship with respect to efficacy of PSL administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy and to evaluate the efficacy of the 4 selected dose regimens of PSL compared with placebo. The secondary objective is to assess the safety and tolerability of all doses of PSL in relation to placebo.
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
    The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) infusion every 4 weeks reduces the frequency of seizures in adult subjects with drug-resistant focal epilepsy.
  • Low frequency electrical stimulation of the fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
    To develop a protocol to evaluate the safety and tolerability of low frequency stimulation of the fornix in patients with MTLE.